Cardiac rehabilitation is safe and effective also in the elderly, but don’t forget about drugs!

La Riabilitazione Cardiologica è sicura ed efficace negli anziani. Però ricordiamoci della terapia farmacologica!

Donatella Del Sindaco¹, Maria Denitza Tinti², Giovanni Pulignano², Stefano Tolone², Giovanni Minardi², Massimo Uguccioni², Antonio Lax¹

¹ Cardiology Unit, Nuovo Regina Margherita Hospital, Rome
² Cardiology 1/CCU, San Camillo Hospital, Rome, Italy

Abstract

In the setting of heart failure (HF) pharmacotherapy demonstrates a quantifiable improvement in exercise tolerance also in HF with preserved ejection fraction (HFrEF). For patients with HFrEF, often older, with higher prevalence of hypertension, diabetes mellitus, atrial fibrillation and other comorbidities, endpoints such as quality of life and functional capacity may be more clinically relevant. However several study show as the use of ACE-I and B-blocker were lesser than expected. Beta-blocker therapy is the keystone of pharmacotherapy of HF patients and exercise training is the essential core of rehabilitation programs, it is important to elucidate the relationship between these therapies. Exercise training improves the clinical status of HF, improving left ventricular ejection fraction and improving quality of life, but it is possible that b-blocker may attenuate exercise training adaptations. Despite this, possible adverse b-blocker effects are just presumed and not confirmed by published randomized clinical trials. Metanalysis suggests that b-blocker compared with placebo enhances improvements in cardiorespiratory performance in exercise training intervention. Despite these evidences, prescription of gold standard therapy and adherence are still suboptimal and should be a priority goal for all CR program.

Introduction

Heart failure (HF) shows an age-related increasing prevalence as a consequence of the aging of the population as well as of the improved long-term survival of patients with ischemic heart disease and hypertension. Moreover, the clinical picture of older heart failure patients is heterogeneous and results from a complex interaction between cardiac disease and age-related changes, comorbidities, geriatric conditions and social issues. However, despite remarkable advances in diagnosis and therapy over the past decades, the prognosis of these patients remains poor, with high rates of hospitalization, readmission, and mortality. For these reasons, published HF RCTs have mainly focused on mortality and hospitalization endpoints, with a lesser attention to exercise tolerance and symptoms.

In HF with reduced ejection function (HFrEF), mortality endpoints do not always correlate well with change in exercise tolerance or quality of life - evident in examples of superior survival with limited or no symptom change [1], and symptomatic improvement without survival benefit [2].
Despite no significant treatment benefits in term of mortality or diastolic function improvement, pharmacotherapy have demonstrated a quantifiable improvement in exercise tolerance also in heart failure with preserved ejection fraction (HFpEF). Although nitrates are commonly prescribed for symptom relief in heart failure, a recent trial showed that HFpEF patients receiving isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo [3]. There is still no clear evidence that heart rate reduction with ivabradine for improving symptoms in a HFpEF population characterized by exercise limitation [4].

As HFpEF patients are more often older, female, have a higher prevalence of hypertension, diabetes mellitus, atrial fibrillation and other concomitant comorbid conditions, endpoints such as quality of life and functional capacity may be more clinically relevant in this setting.

Evidence-based prescriptions in CR

The quality of care of older heart failure patients is often far to be satisfactory in clinical practice. Thus, the relative ‘under use’ of evidence-based treatments largely appears to depend on the higher complexity and the lack of definite evidence on efficacy and safety of nonpharmacological and pharmacological treatments in the very elderly. Indeed, effective heart failure treatments such as angiotensin-converting enzyme (ACE) inhibitors, aldosterone antagonists, or beta blockers may be considered not indicated in the elderly because of the high prevalence of renal vascular disease, renal impairment, diabetes, COPD and other various reasons. Multidrug therapy is a common feature in older patients, with multiple cardiovascular and noncardiovascular medications used for several associated diseases. Drug interactions and adverse reactions are common when multiple medications are prescribed for elderly patients. Thus the older heart failure population, which in fact comprises the majority of all patients, is in general less well studied, both experimentally and clinically, than younger populations. Older patients are generally underrepresented in randomized clinical trials because only a few of them have addressed the impact of therapy in patients aged more than 70-years-old and virtually none included patients aged more than 85-years-old. These observations are likely dependent on the eligibility criteria of clinical trials, in which only patients with a poor LVEF and without significant comorbidities are included, whereas preserved systolic function and comorbidities frequently characterize elderly people. The main reason is that ACE inhibitors, beta-blockers, angiotensin receptor antagonists and aldosterone antagonists have shown a benefit in terms of mortality and rehospitalization only in patients with a mean age of 63 and reduced LVEF, and the evidence on the effects in elderly patients and those with preserved systolic function are still limited. As a consequence, recent guidelines pointed out the lack of adequate knowledge on heart failure treatment in the elderly.

For similar reasons it’s difficult to weight benefits of HF therapy in CR settings, as HF therapy implementation and titration to target doses is very inconstant among all trials and in the real world of clinical practice.

In the largest CR trial, the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) which enrolled 2331 patients with heart failure and reduced ejection fraction with a median age of 59 years (28% were women, median follow-up 30.1 months), at 12 months of follow-up, ACE inhibitor or ARB use was 93.3% in the usual care group versus 95.3% in the exercise training group, while beta-blocker use was 95% in the usual care group and 94% in the exercise training group [2].

In the HF-ACTION study, use of b-blockade was a baseline covariate predictor of survival, which is perhaps not surprising considering the link between peak oxygen consumption (VO_2) and mortality in HF patients. There was no significant interaction of exercise training with beta-blocker use.

Conversely, in a smaller CR study involving fifty-nine patients aged 60 and older with HFpEF HF drugs were prescribed far below previous statistics; in this study mean age was 70±5 (range 60-80), substantially greater than reported in most prior studies of CR in HFpEF, including HF-ACTION, and the frequency of beta-blockers was relatively modest (10% in all patients, with no significantly different differences between CR group)

Likewise, in a trial studying the effect of exercise in 63 older patients with HFpEF (mean age 70±7 years), both ACE-Inhibitors and beta-blockers were prescribed lesser than expected (for beta-blockers: 9% in CR group vs 35 in control group, p=0.02: for ACE-I 30% in CR group vs 24% in control group, p=0.44) [6].

In particular settings, such as in CR after transcatheter aortic valve implantation (TAVI), implementing gold standard therapy is particularly challenging, mainly because of high rates of frailty and comorbidities among these patients.

In a study aimed at comparing CR program in octogenarians (mean age 83±3.6 years) after a conventional surgical aortic valve replacement versus TAVI, beta-blockers were prescribed in 57% of patients while ACE-Inhibitors in 51.3% [7].

Nevertheless, in previous experiences, basing on physiopathology, concern was raised about the effects of beta-blockers on exercise tolerance, especially regarding those with intrinsic sympathomimetic activity, for a smaller reduction in heart rate compared with b-blockers without ISA and a supposed inferior effect on exercise capacity.

Beta-blockers and exercise

During past decades, large observational studies, retrospective subgroup analyses and meta-analyses of clinical trials in systolic heart failure, and recently published randomized studies have provided data supporting the use of beta-blockers as a baseline therapy in heart failure in the elderly. Despite the available evidence about beta-blockers, this therapy is still less frequently used in elderly compared to younger patients. As beta-blocker therapy is the keystone of pharmacotherapy of HF patients and exercise training is the essential core of rehabilitation programs, it is important to elucidate the relationship between these therapies.

Exercise training improves the clinical status of HF patients by increasing peak VO_2 [8], improving left ventricular ejection fraction (LVEF), lowering systemic brain natriuretic peptide (BNP) [8], and improving quality of life [9], but it is possible that b-blockers may attenuate exercise training adaptations.

Despite this, possible adverse b-blocker effects are just presumed and not confirmed by published randomized clinical trials and, if the effects on exercise capacity are better understood, many more patients eligible to use these drugs may assume them with better compliance.

A metaanalysis from several trials has examined whether b-blockers weaken the effects of exercise training in HF patients, suggesting that b-blockade compared with placebo actually enhances improvements in cardiorespiratory performance in exercise training intervention; moreover, there was no difference between selective and nonselective b-blockade as no drug of both classes appeared to attenuate exercise training-induced adaptations for HF patients.

Improvements in all outcome measures suggest that b-blockade, unless contraindicated by comorbidities, enhances exercise training-
induced adaptations and unsupported suggestions that b-blockade worsens exercise capacity should not influence physicians’ and patients’ choices in pharmacotherapy [10].

In particular, with respect to elderly HF patients, in a subgroup of patients aged over 65 of the CIBIS-ELD study group undergone Doppler echocardiography and cardiopulmonary exercise testing before BB therapy and after 12 weeks, bisoprolol significantly reduced heart rate and systolic blood pressure at rest and during exercise (heart rate from 80.3±14.2 bpm to 73.8±11.1 bpm, p=0.034 and from 117.4±20.5 bpm to 110.7±20.6 bpm, p=0.036, respectively; systolic blood pressure from 132.5±24.0 mmHg to 128.1±12.9 mmHg, p=0.043, and from 186.7±20.6 mmHg to 177.7±26.3 mmHg, p=0.930), with sustained level of peak VO2; also, according to Borg score, symptoms of breathlessness were significantly reduced (from 6.76 to 5.76, p=0.001) [11].

How to improve adherence?

Basing on these data, it’s mandatory to prevent withdrawal from beta-blocker treatment and, in general, from evidence-based therapies. Although evidences confirm that HF gold standard therapies improve exercise tolerance, low therapy adherence is still a key issue in CR.

Standard drug regimens for HF have become more complex in the last 15 years, due to the multiple therapeutic targets that exist and the need for routine symptomatic management.

Non-adherence to medication regimens is a common problem among patients with HF, and it limits the potential benefit of these drugs. Studies estimate that 30-60% of patients with HF do not assume medications as prescribed [12]. In fact, non-adherence is suggested to be the most common cause of preventable re-hospitalizations.

In the setting of HF adherence or compliance to medication is a component of self care. Self-care is a complex and multi-dimensional process, which also includes behaviors like diet and exercise, self-management, and seeking assistance when symptoms occur or weighing daily. Thus, self-care is influenced by a number of patient factors, such as knowledge of HF and its symptoms, previous experience, skills, coping strategies, cognitive status, and caregivers’ support.

There are many potential reasons for the observed low levels of adherence, including the complexity of treatment regimens, side effects, cognitive impairment, poor understanding of the benefits of treatment and lack of disease knowledge, lack of support (eg, caregiver), difficulty in accessing physicians and pharmacies, confusion associated with taking medicines and polypharmacy [13].

In those patients a higher number of comorbid conditions and polypharmacy predict poor medication adherence. Having multiple conditions also decreases self-efficacy in performing specific self-care tasks such as medication taking [14].

Recognizing the weight of this management issue, the ACC/AHA/ACCF guideline on HF recommends that healthcare providers should be aware of the importance of taking appropriate preventive medications[15].

In this perspective, a rapid assessment of cognitive function and psychological status in older patients may lead to a more tailored follow-up and structured education in order to reduce the risk of non adherence to therapy, and, subsequently, worse self-care and related adverse consequences. Thus, in clinical practice, a structured follow-up of older patients, including written and verbally given care instructions, medication or dietary changes, caregiver surveillance and careful monitoring should be adopted (Table 1).

### Table 1. How to facilitate adherence.

1. Initiate communication on the nature of the disease and need of therapy immediately after admission to hospital (time of maximum motivation to change);
2. Provide detailed information on the prescribed therapy and mode of follow-up after discharge directly to the patient;
3. Promote optimal contact between patient and operators health, by providing:
   - adequate duration of the pre-dismissal interview,
   - the first post-discharge control in the short term (30 days),
   - adequate duration of follow-up visits,
   - possibility of direct or dial-in the case of specific clinical problems;
4. Identify factors associated with non-adherence and use of specific tools occurs task during follow-up as the morisky questionnaire;
5. Use the telephone recall especially in subjects at high risk.

In conclusion HF therapy plays a key role in enhancing exercise tolerance in HF patients, also in the elderly and in those with HFpEF. Despite these evidences, prescription of gold standard therapy is still low, particularly in frail patients and in those with multiple comorbidities. As a consequence, adherence is still suboptimal and should be a priority goal for all CR program. It is also evident that targeted clinical trials and rigorous observational studies are needed, aiming at developing more effective treatments and favoring the implementation of specific guidelines into clinical practice.

### References


